During breast cancer progression, DCs engage in phagocytosis of apoptotic tumor cells, process and present tumor antigens on MHC-I and MHC-II molecules, migrate to local lymph nodes, and present antigens to naive CD4+ and CD8+ T cells to elicit an anti-tumor immune response (125, 126). This evidence concerns the gene CD8A and neoplasm.